The primary targets are the distinctive surface proteins of CTCs, such as EpCAM [106], which can be used as an oncogenic biomarker because it has been demonstrated in numerous studies that EpCAM is overexpressed on CTCs from different types of human cancers, leading to the frequent use of anti-EpCAM compounds in CTC screening. Here, EPCAM is linked to cancer.